- Home
- CBRL vs MESO Comparison
CBRL vs MESO Comparison
Compare CBRL & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRL
- MESO
- Stock Information
- Founded
- CBRL 1969
- MESO 2004
- Country
- CBRL United States
- MESO Australia
- Employees
- CBRL N/A
- MESO N/A
- Industry
- CBRL Restaurants
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CBRL Consumer Discretionary
- MESO Health Care
- Exchange
- CBRL Nasdaq
- MESO Nasdaq
- Market Cap
- CBRL 1.3B
- MESO 1.3B
- IPO Year
- CBRL N/A
- MESO N/A
- Fundamental
- Price
- CBRL $66.88
- MESO $10.98
- Analyst Decision
- CBRL Hold
- MESO Buy
- Analyst Count
- CBRL 8
- MESO 4
- Target Price
- CBRL $53.86
- MESO $18.00
- AVG Volume (30 Days)
- CBRL 1.3M
- MESO 221.7K
- Earning Date
- CBRL 06-05-2025
- MESO 08-28-2025
- Dividend Yield
- CBRL 1.50%
- MESO N/A
- EPS Growth
- CBRL N/A
- MESO N/A
- EPS
- CBRL 2.58
- MESO N/A
- Revenue
- CBRL $3,510,062,000.00
- MESO $5,670,000.00
- Revenue This Year
- CBRL $1.97
- MESO $178.09
- Revenue Next Year
- CBRL $1.61
- MESO $305.06
- P/E Ratio
- CBRL $25.94
- MESO N/A
- Revenue Growth
- CBRL 2.84
- MESO N/A
- 52 Week Low
- CBRL $33.86
- MESO $5.78
- 52 Week High
- CBRL $68.09
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- CBRL 65.36
- MESO 45.40
- Support Level
- CBRL $59.29
- MESO $9.88
- Resistance Level
- CBRL $68.08
- MESO $12.50
- Average True Range (ATR)
- CBRL 3.21
- MESO 0.36
- MACD
- CBRL 0.57
- MESO -0.02
- Stochastic Oscillator
- CBRL 91.51
- MESO 30.53
About CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The restaurants of the company are open for breakfast, lunch, and dinner, with menus that offer home-style country food. The company generates maximum revenue from the Restaurants.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.